Get informed when a big investor buys or sells
+ FollowNovember 5, 2026 - AI Summary
Overvalued by 103.3% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $31.01 Billion |
|---|---|
| Enterprise Value | $33.44 Billion |
| Annual dividend | $0.16 |
| Dividend yield | 1.44% |
| Earnings per Share | $1.35 |
| Beta | 0.62 |
| Outstanding Shares | 469,750,000 |
| P/E Ratio | 40.92 |
|---|---|
| PEG | 111.42 |
| Price to Sales | 7.33 |
| Price to Book Ratio | 2.87 |
| Enterprise Value to Revenue | 7.62 |
| Enterprise Value to EBIT | 33.55 |
| Enterprise Value to Net Income | -165 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.26 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 0.00% |
|---|---|
| Total Invested | $1.38M▼ 6.09% |
| Investors Holding | 6▼ 3.00% |
Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends ...